Oxford Asset Management LLP Buys 2,859 Shares of Cencora, Inc. (NYSE:COR)

Oxford Asset Management LLP grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 117.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,298 shares of the company's stock after purchasing an additional 2,859 shares during the period. Cencora comprises about 0.6% of Oxford Asset Management LLP's portfolio, making the stock its 28th largest position. Oxford Asset Management LLP's holdings in Cencora were worth $1,190,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Hickory Asset Management Inc. bought a new stake in Cencora in the 4th quarter valued at $572,000. Sylvest Advisors LLC acquired a new stake in Cencora in the 4th quarter valued at $1,105,000. Insight Wealth Strategies LLC increased its stake in Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after buying an additional 11,232 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after buying an additional 1,995 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its stake in Cencora by 71.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock valued at $1,583,000 after buying an additional 2,928 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of Cencora stock traded down $1.10 during trading hours on Thursday, hitting $291.58. 481,166 shares of the company's stock traded hands, compared to its average volume of 1,519,520. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The stock has a market capitalization of $56.54 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 1.31 and a beta of 0.55. The company has a fifty day simple moving average of $270.90 and a 200-day simple moving average of $250.57. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Wall Street Analyst Weigh In

COR has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. UBS Group boosted their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Finally, Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $290.00.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares of the company's stock, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 in the last quarter. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.